載入...
Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease
Certolizumab pegol (CZP), an anti–tumor necrosis factor α agent, is an effective therapy for Crohn's disease (CD). A population pharmacokinetic (PK) analysis of subcutaneously administered CZP was performed using data from 2157 CD patients from 9 separate studies. The aim was to determine which...
Na minha lista:
| 發表在: | J Clin Pharmacol |
|---|---|
| Main Authors: | , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley and Sons Inc.
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6680228/ https://ncbi.nlm.nih.gov/pubmed/25735646 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.491 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|